Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b.
Deutsch
Melanie
M
Academic Department of Internal Medicine, Hippokration General Hospital, Athens, Greece. kostam@ath.forthnet.gr
Manesis
Emanuel K
EK
Hadziyannis
Emilia
E
Vassilopoulos
Dimitrios
D
Archimandritis
Athanasios J
AJ
D051722:ADAM Proteins / Q000097:blood / Q000172:deficiency / Q000276:immunology; D000071120:ADAMTS13 Protein; D000998:Antiviral Agents / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008875:Middle Aged; D011092:Polyethylene Glycols; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood / Q000139:chemically induced* / Q000276:immunology; D011994:Recombinant Proteins
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human; C417083:peginterferon alfa-2b